In the presence of PARP inhibitors, the PARP-dependent DNA repair system cannot be activated leading to the development of double-strand breaks and susceptibility of BRCA1/2-mutant breast cancer cells for instance to synthetic lethality (Farmer et al. 2005; Bryant et al. 2005). This evidence concerns the gene PARP1 and breast carcinoma.